None listed
Conditions
Brief summary
Adenosine has never been studied in coronary angioplasty in the setting of non ST segment elevation acute coronary syndrome. With promising observations of the benefits of adenosine in both elective and primary angioplasty settings, we hypothesise that intracoronary adenosine may prevent myocyte death (periprocedural myonecrosis) in this groups of patients undergoing coronary angioplasty. We hypothesise that pretreatment with a intracoronary bolus dose of adenosine before coronary angioplasty decreases the amount of periprocedural myonecrosis in patients with non ST segment elevation acute coronary syndrome
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
Patients presenting with non ST segment elevation acute coronary syndrome (NSTEACS)
Exclusion criteria
ST segment elevation myocardial infarction (STEMI), Cardiogenic Shock, bradycardia or Atrioventricular (AV) block, refractory ventricular arrhythmias, severe asthma, allergy to adenosine, totally occluded arteries resulting in TIMI grade 0 antegrade flow, pregnancy, unconscious or not for resuscitation,